I'd guess that's our stumbling block to a deal. Was the Ph2 data...

First 62 Last

Share
Profile

Follow
mickqld

2,154 Posts.

40

08/03/18

13:47

Post #: 31619731
Share

Originally posted by TripAces ↑

Hottod i emailed Joe and asked his thoughts on whether Big Pharma cash repatriation will/is leading to premium deal prices. I also mentioned my interest in NEU and his comments are below for those interested:

Thanks for your note and interest in my presentation.

It’s a bit early to see the true effect of the tax and financial law changes in the US. However, I feel it’s safe to say it will materially increase investment by US-based large pharma companies. They might be willing to up the ante on deal value a bit. But, a more likely (and more immediate) result will be for deal values to continue the steady upward growth we’ve had for years; with pharma doing more deals per year on average. Most larger pharmas know value is value when it comes to external assets; and higher bank account balances don’t usually make them think they have to pay more for the same asset. I don’t think the increased deal volume will have a near-term direct effect of driving up deal values.

As far as Neuren, I’d have to take a closer look to say much definitively. At first blush, I’d say they’re 1) targeting indications of significant partner interest, and 2) are targeting indications with historically high failure rates for drugs in development. These two work against each other in partnering. I’d look more closely at competing drugs in development using the IGF-1 pathway and those with different MOAs. Also, I’d want to compare the Neuren’s PII efficacy data to end points desired by partners. Do partners have better choices out there? Is their data good enough to do a deal now, or would a partner be wise to wait for better data with this asset or watch for a different MOA to generate data?

Hope that helps some……….

Expand

I'd guess that's our stumbling block to a deal. Was the Ph2 data enough to push thru a deal or does big pharma have the luxury to wait on better data or someone else with something better ??

NEU Price at posting: $3.10 Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

What's causing the cost-of-living crisis, and how to navigate it